Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multicenter, Open-Label, First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD 001 in Patients with Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase I, Multicenter, Open-Label, First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD 001 in Patients with Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD 001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 20 Feb 2025 According to a Chengdian Bio media release, CD-001 has officially obtained implicit clinical trial approval from the National Medical Products Administration ( NMPA ) (acceptance number: CXSL2400701 ) for the treatment of advanced solid tumors.
    • 27 Sep 2024 New trial record
    • 20 Sep 2024 According to a CD (Suzhou) Biopharma media release, company has received clearance from the U.S. Food and Drug Administration (FDA) for CD-001, entering a Phase I first-in-human trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top